CIM
CORT icon

Contravisory Investment Management’s Corcept Therapeutics CORT Stock Holding History

Contravisory Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-183
Closed -$6.37K – 381
2025
Q4 		$6.37K Hold
183
– – ﹤0.01% 348
2025
Q3 		$15.2K Hold
183
– – ﹤0.01% 323
2025
Q2 		$13.4K Buy
+183
New +$13.3K ﹤0.01% 328
2023
Q1 		– Sell
-216
Closed -$4.39K – 334
2022
Q4 		$4.39K Hold
216
– – ﹤0.01% 297
2022
Q3 		$6K Hold
216
– – ﹤0.01% 265
2022
Q2 		$5K Hold
216
– – ﹤0.01% 275
2022
Q1 		$5K Buy
+216
New +$4.59K ﹤0.01% 290

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Contravisory Investment Management's CORT Position: Q1 2026 in Review

Contravisory Investment Management sold out of Corcept Therapeutics (CORT) in Q1 2026, closing a stake of 183 shares — an estimated $6.37K sold.

Contravisory Investment Management first reported a position in CORT in Q1 2022 and held it in 7 quarters. The position peaked at $15.2K in Q3 2025. 352 funds tracked by Wall St. Rank hold CORT as of Q1 2026.

  • Contravisory Investment Management reported no remaining Corcept Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Contravisory Investment Management sold 183 Corcept Therapeutics shares in Q1 2026, an estimated $6.37K.
  • Contravisory Investment Management first reported a position in Corcept Therapeutics in Q1 2022 and held it in 7 quarters.
  • Contravisory Investment Management's Corcept Therapeutics position peaked at $15.2K in Q3 2025.
  • 352 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2026.

Based on Contravisory Investment Management's 13F filing for Q1 2026, filed 20 Apr 2026.